Abstract
The success of chimeric antigen receptor (CAR) Tcell therapy in solid tumors, unlike in hematologic malignancies, is limited by inadequate tumor infiltration and Tcell dysfunction and exhaustion. Regional delivery of CAR Tcells in patients with solid tumors is safe and feasible; promotes infiltration, proliferation, and trafficking; and ignites functionally persisting systemic immunity.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Paper version not known
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
